BioSpace News Archive

Spectrum Pharmaceuticals, a biopharmaceutical company focused on novel and targeted oncology therapies, announced a poster presentation titled: High Activity of Poziotinib in G778_P780dup HER2 Exon 20 Insertion Mutations in Non-Small Lung Cancer.

AstraZeneca’s IMFINZI® has been approved in the US for the treatment of adult patients with locally advanced or metastatic biliary tract cancer in combination with chemotherapy.

Regeneron Pharmaceuticals, Inc. and Sanofi announced results from a Phase 3 open-label extension trial demonstrating the efficacy and safety profile of Dupixent® as a maintenance therapy when added to other asthma medications was consistent for up to two years in children aged 6 to 11 years with uncontrolled moderate-to-severe asthma with evidence of type 2 inflammation.

Apexigen, Inc. a clinical-stage company focused on developing innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology, announced the presentation of new data from a Phase 2 clinical trial evaluating sotigalimab, Apexigen’s agonist antibody targeting CD40, in combination with neoadjuvant chemoradiation for patients with resectable esophageal and gastroesophageal junction cancers.

Synthetic Biologics, Inc., a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, announced a presentation of initial data from a Phase 1 investigator-sponsored study evaluating VCN-01 in combination with durvalumab for patients with recurrent/metastatic squamous cell carcinoma of the head and neck.

Tyra Biosciences, Inc. announced that the Company will be presenting preclinical data on TYRA-300 during a poster session at the European Society for Medical Oncology 2022 Congress, being held in person September 9-13, 2022 in Paris, France.

Boehringer Ingelheim announced Phase III data from the InPedILD trial, which assessed the pharmacokinetics and safety profile of nintedanib in children and adolescents between 6 and 17 years old with clinically significant fibrosing interstitial lung disease.

Biotimize, a functional growth-stage biotechnology as a service company with a mission to transform lives through biotechnology, announced the opening of a $30 million Series A fundraising round.

Bristol Myers Squibb announced the presentation of scientific research across several solid tumors showcasing the breadth of the Company’s oncology development program at the European Society for Medical Oncology Congress 2022 from September 9-13 in Paris, France.

Lunit announced the presentation of five abstracts highlighting the effectiveness of its AI-biomarker platform - Lunit SCOPE - at the European Society of Medical Oncology Congress 2022, held in Paris from September 9 to 13.